Evaluate the Effect of Vimseltinib on the Pharmacokinetics of a BCRP and OATP1B1 Substrate
Completed · Phase 1 · NCT07158398
Conditions: Healthy Participants
At a glance
- Research payments reported, 2025
- $1.1M
- U.S. investigators named
- 1
- Sites paid
- 2
- Planned or actual enrollment
- 20
About the trial
- Sponsor
- Deciphera Pharmaceuticals, LLC
- Tested
- Vimseltinib (drug), Rosuvastatin (drug)
- Dates
- Started 2025-10-31; completion 2025-12-08
- Results posted
- Not yet
The main purpose of this study is to determine the effect of Vimseltinib dosing on breast cancer resistance protein (BCRP) and organic-anion-transporting polypeptide 1 B1 (OAT1PB1) activity by using rosuvastatin in healthy male participants. This study will also evaluate the safety and tolerability when vimseltinib is co-administered with rosuvastatin in healthy male participants. This study will last approximately 26 days.
From ClinicalTrials.gov, last updated 2026-01-15. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Deciphera Pharmaceuticals Inc. reported $1.1M in research payments for this study in 2025 (11 payments).
Products named: Rosuvastatin
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Dr Vince Clinical Research $1.1M
- Dr Vince Clinical Resarch LLC $1,634
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.